Precigen completes sale of non-healthcare subsidiary trans ova genetics

–  proceeds include $170 million in upfront cash and up to $10 million earn-out over two years – germantown, md. , aug. 22, 2022 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the company has completed the sale of its wholly-owned non-healthcare subsidiary, trans ova genetics, l.c.
PGEN Ratings Summary
PGEN Quant Ranking